INCB 50465

Drug Profile

INCB 50465

Alternative Names: INCB-050465; INCB-50465

Latest Information Update: 29 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Incyte Corporation
  • Class Antineoplastics
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma; Follicular lymphoma; Myelofibrosis
  • Phase I/II B cell lymphoma; Solid tumours

Most Recent Events

  • 04 Aug 2017 Incyte plans a phase II trial for Mantle cell lymphoma (Second-line therapy or greater, Refractory metastatic disease) (NCT03235544)
  • 29 Jun 2017 Phase-II clinical trials in Follicular lymphoma (Second-line therapy or greater) in USA (PO) (NCT03126019)
  • 25 Jun 2017 Adverse events data from the phase I/II CITADEL-101 trial in B-cell lymphoma presented at the 22nd Congress of the European Haematology Association (EHA-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top